133 related articles for article (PubMed ID: 9250283)
1. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis.
Clerici C; Distrutti E; Gentili G; Solinas A; Miglietti M; Balò S; Giansanti M; Rusticali AG; Morselli-Labate AM; Morelli A
Minerva Med; 1997 May; 88(5):219-25. PubMed ID: 9250283
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.
Senturk H; Uzunalimoglu O; Batur Y; Simsek I; Mert A; Ozbay G; Cetinkaya H; Ersoz G; Tabak F; Akbaylar H; Akdogan M; Dokmeci A; Sonsuz A; Ozenirler S; Erden E; Tozum N
Dig Dis Sci; 1997 Jul; 42(7):1438-44. PubMed ID: 9246043
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients.
Fabbri C; Marchetto S; Pezzoli A; Accogli E; Fusaroli P; Azzaroli F; Jaboli MF; Mazzeo C; Montagnani M; Festi D; Roda E; Mazzella G
Eur J Gastroenterol Hepatol; 2000 May; 12(5):511-5. PubMed ID: 10833093
[TBL] [Abstract][Full Text] [Related]
4. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.
Boucher E; Jouanolle H; Andre P; Ruffault A; Guyader D; Moirand R; Turlin B; Jacquelinet C; Brissot P; Deugnier Y
Hepatology; 1995 Feb; 21(2):322-7. PubMed ID: 7843700
[TBL] [Abstract][Full Text] [Related]
5. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial.
Tanaka K; Kondo M; Sakaguchi T; Saito S; Arata S; Ikeda M; Kitamura T; Morimoto M; Sekihara H
J Gastroenterol Hepatol; 1996 Dec; 11(12):1155-60. PubMed ID: 9034935
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease.
Lirussi F; Beccarello A; Bortolato L; Morselli-Labate AM; Crovatto M; Ceselli S; Santini G; Crepaldi G
Liver; 1999 Oct; 19(5):381-8. PubMed ID: 10533795
[TBL] [Abstract][Full Text] [Related]
8. Effect of interferon, ribavirin and ursodeoxycholic acid in patients with hepatitis C infection.
Ljubuncic P; Konikoff FM; Blendis LM; Bomzon A
Hepatogastroenterology; 2005; 52(64):1191-6. PubMed ID: 16001659
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon.
Poupon RE; Bonnand AM; Queneau PE; Trépo C; Zarski JPí ; Vetter D; Raabe JJ; Thieffin G; Larrey D; Grangé JD; Capron JP; Serfaty L; Chrétien Y; St Marc Girardin MF; Mathiex-Fortunet H; Zafrani ES; Guéchot J; Beuers U; Paumgartner G; Poupon R
Scand J Gastroenterol; 2000 Jun; 35(6):642-9. PubMed ID: 10912666
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial.
Abdelmalek MF; Harrison ME; Gross JB; Poterucha JJ; Gossard AA; Spivey JR; Rakela J; Lindor KD
J Clin Gastroenterol; 1998 Mar; 26(2):130-4. PubMed ID: 9563925
[TBL] [Abstract][Full Text] [Related]
11. Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients.
Boucher E; Guyader D; Jacquelinet S; Andre P; Mendler MH; Turlin B; Canva V; Nousbaum JB; Bernard PH; Nouel O; Raabe JJ; Dao T; Gasser P; Verger P; Boutin J; Bergerault P; Joram F; Colmar P; Messner M; Brissot P; Deugnier Y
Dig Liver Dis; 2000; 32(1):29-33. PubMed ID: 10975752
[TBL] [Abstract][Full Text] [Related]
12. Interferon versus interferon and UDCA combined therapy in chronic hepatitis C.
Mazur W; Machniak M; Mazurek U; Jurzak M; Wilczok T; Gonciarz Z
Med Sci Monit; 2001 May; 7 Suppl 1():157-64. PubMed ID: 12211712
[TBL] [Abstract][Full Text] [Related]
13. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group.
Niederau C; Strohmeyer G; Heintges T; Peter K; Göpfert E
Hepatogastroenterology; 1998; 45(21):797-804. PubMed ID: 9684137
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C.
Lu CL; Chan CY; Hwang SJ; Lu RH; Lee SD
J Gastroenterol Hepatol; 1995; 10(4):432-7. PubMed ID: 8527710
[TBL] [Abstract][Full Text] [Related]
15. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS
Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
[TBL] [Abstract][Full Text] [Related]
16. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
17. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
18. Improvement of alanine aminotransferase by administration of suplatast tosilate plus ursodeoxycholic acid in patients with resistance to ursodeoxycholic acid monotherapy on hepatitis C virus-related chronic liver disease.
Matsuda Y; Inada M; Maeda H; Matsuyama T
Intern Med; 2002 Oct; 41(10):774-9. PubMed ID: 12412994
[TBL] [Abstract][Full Text] [Related]
19. Rat liver fibrosis regresses better with pegylated interferon alpha2b and ursodeoxycholic acid treatments than spontaneous recovery.
Tasci I; Mas MR; Vural SA; Comert B; Alcigir G; Serdar M; Mas N; Isik AT; Ates Y
Liver Int; 2006 Mar; 26(2):261-8. PubMed ID: 16448466
[TBL] [Abstract][Full Text] [Related]
20. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C.
Younossi ZM; Perrillo RP
Semin Liver Dis; 1999; 19 Suppl 1():95-102. PubMed ID: 10349697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
